News & Analysis as of

Manufacturers › Johnson & Johnson › Prescription Drugs

Quarles & Brady LLP

Manufacturer Rebate Models: The Next 340B Program Battleground

Quarles & Brady LLP on

The 340B Drug Pricing Program (“340B Program”) space continues to be a hive of activity. While 340B stakeholders continue to litigate ongoing manufacturer contract pharmacy restrictions, states legislatures are enacting...more

Hicks Johnson

Public Nuisance Claim Loses Traction in Oklahoma Opioid Case; Ohio, California Cases Move Forward

Hicks Johnson on

The past year saw several attempts to apply new applications of the public nuisance doctrine to the opioid crisis. While in the past, public nuisance claims typically sought recovery for damages in connection with land use in...more

Husch Blackwell LLP

Oklahoma Supreme Court Sets Aside $465 Million Public Nuisance Opioid Verdict

Husch Blackwell LLP on

On November 9, 2021, the Oklahoma Supreme Court set aside a $465 million verdict against Johnson & Johnson (J&J) in State ex rel. Hunter v. Johnson & Johnson, 2021 OK 54. In 2017, the State of Oklahoma sued three opioid...more

Searcy Denney Scarola Barnhart & Shipley

Lawsuits Involving Fluoroquinolones Piling Up Against Manufacturers

Searcy Denney Scarola Barnhart & Shipley on

Google “fluoroquinolones,” and page after page of search results come up about the dangers, risks and side effects of the antibiotic. Articles appear citing arrhythmia, nerve damage and type 2 diabetes all being associated...more

4 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide